2021 treatments in review, by Mark Scholz, MD, Prostate Cancer Research Institute
What’s New
- Brachytherapy vs EBRT vs SBRT for Low/Intermediate Risk Disease
- FDA Expedites Review of Nubeqa Combination for Metastatic, Hormone-Sensitive Prostate Cancer
- Importance of Lifestyle and Prevention of Complications in Advanced Prostate Cancer
- “Shooting for the Moon” Means Reducing Metastatic Prostate Cancer Diagnoses
- Genetically Adjusted PSA Screening